Jefferies initiated coverage of Elanco with a Buy rating and $17 price target. The firm sees an attractive set up into 2024 for this top player in animal health, and despite recent market underperformance, expects tailwinds from impending product launches to bolster the recent inflection to growth, the analyst tells investors in a research note. An updated product mix post-launch could drive revenue growth and margin expansion though low expectations are priced in, the firm contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ELAN:
- Elanco just upgraded at Morgan Stanley, here’s why
- Elanco upgraded to Overweight from Equal Weight at Morgan Stanley
- Ancora builds stake in Elanco Animal Health, pushes for changes, Bloomberg says
- Elanco price target raised to $13 from $12 at Stifel
- Elanco initiated with an Outperform at Exane BNP Paribas
